Somatic mutations in the epidermal growth factor receptor (EGFR) gene are present in
approximately 20%(in Caucasians) to 40%(in East Asians) of adenocarcinomas of the lung …

Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

Uncommon epidermal growth factor receptor (EGFR) mutations collectively account for 10%
of EGFR mutations, harboring heterogeneous molecular alterations within exons 18–21 with …

Sensitizing mutations in epidermal growth factor receptor (EGFR) are associated with
positive responses to anti-EGFR-targeted therapy, leading to a new era of treatment for non …

The development of first-, second-, and third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC …

Most patients with non‐small cell lung cancer (NSCLC) harboring common epidermal
growth factor receptor (EGFR) mutations, such as deletions in exon 19 or the L858R …

Background: advanced-stage non-small cell lung cancer (NSCLC) is characterized by
having limited treatment options and thus a poor prognosis. However, new treatment …

Background and aims: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR
TKIs) are effective against classical EGFR mutations in lung cancer. However, their …